IN THE CLAIMS

Please amend the claims as follows:

Claims 1-8 (Canceled)

9. (New) A process for stabilizing a Fosfomycin Tromethamol composition, the process comprising:

combining Fosfomycin Tromethamol with at least one of the following substances in an amount effective to stabilize the Fosfomycin Tromethamol:

a tribasic sodium citrate;

a tribasic potassium citrate;

a monoacidic sodium citrate;

a monoacidic potassium citrate;

a tribasic sodium phosphate;

a tribasic potassium phosphate;

a monoacidic sodium phosphate;

a monoacidic potassium phosphate;

a sodium carbonate;

a ~~phosphate~~ potassium carbonate;

a sodium bicarbonate;

a ~~phosphate~~ potassium bicarbonate;

a sodium tartrate;

a ~~phosphate~~ potassium tartrate;

an arginine; and

a lysine.

10. (Previously Presented) The process of claim 9, wherein the stabilizing substance is one or more of: a tribasic sodium citrate, a sodium carbonate, a potassium carbonate, a sodium bicarbonate, a potassium bicarbonate, and an arginine.

11. (Previously Presented) The process of claim 9, wherein a molar ratio of the substance with respect to Fosfomycin Tromethamol is in a range between 10% and 100%.

12. (Previously Presented) The process of claim 9, wherein a molar ratio of the substance with respect to Fosfomycin Tromethamol is in a range between 30% and 70%.

13. (Previously Presented) The process of claim 9, wherein a molar ratio of the substance with respect to Fosfomycin Tromethamol is at least 50%.

14. (Previously Presented) The process of claim 9, wherein the Fosfomycin Tromethamol and the stabilizing agent are produced as a hydrosoluble granulate.

15. (Previously Presented) The process of claim 9, wherein the Fosfomycin Tromethamol is present in the composition in an amount of approximately 5.6 g.

16. (Previously Presented) The process of claim 9, further comprising adding an excipient agent.

17. (Currently Amended) A pharmaceutical composition comprising Fosfomycin Tromethamol and at least one substance, in an amount effective for stabilizing, selected from the group consisting of:

a tribasic sodium citrate;

a tribasic potassium citrate;

a monoacidic sodium citrate;

a monoacidic potassium citrate;

a tribasic sodium phosphate;

a tribasic potassium phosphate;

a monoacidic sodium phosphate;

a monoacidic potassium phosphate;

a sodium carbonate;

a ~~phosphate~~ potassium carbonate;

a sodium bicarbonate;

a ~~phosphate~~ potassium bicarbonate;

a sodium tartrate;

a ~~phosphate~~ potassium tartrate;

an arginine; and

a lysine.

18. (Previously Presented) The pharmaceutical composition of claim 17, wherein the stabilizing substance is one or more of: a tribasic sodium citrate, a sodium carbonate, a potassium carbonate, a sodium bicarbonate, a potassium bicarbonate, and an arginine.

19. (Previously Presented) The pharmaceutical composition of claim 17, wherein a molar ratio of the substance with respect to Fosfomycin Tromethamol is in a range between 10% and 100%.

20. (Previously Presented) The pharmaceutical composition of claim 17, wherein a molar ratio of the substance with respect to Fosfomycin Tromethamol is in a range between 30% and 70%.

21. (Previously Presented) The pharmaceutical composition of claim 17, wherein a molar ratio of the substance with respect to Fosfomycin Tromethamol is at least 50%.

22. (Previously Presented) The pharmaceutical composition of claim 17, wherein the Fosfomycin Tromethamol is present in an amount of approximately 5.6 g.

23. (Previously Presented) The pharmaceutical composition of claim 17, which is produced as a hydrosoluble granulate.